Vital Sensors to Present at Medtech Insight's ``In Circulation'' Conference.

CHICAGO -- Vital Sensors GmbH:

--Vital Sensors has announced that it will be presenting at 9:55 am at Medtech Insight's Prestigious "In Circulation: Strategic Partnering and Investing in Circulatory Medicine" Conference, taking place April 27, 2005 at the Hyatt Regency McCormick Place in Chicago, IL.

Vital Sensors GmbH, an emerging medical devices company, realizes telemetric sensing products, representing a major advance in the management of congestive heart failure (CHF).

CHF affects over 20 million people worldwide. In the US alone, some 5.5 million people have been diagnosed with heart failure. It is estimated that heart failure cost the US economy more than $40 billion annually today.

Left atrial pressure (LAP) management is the mainstay of heart failure treatment, but physicians need greatly improved information on LAP to improve outcomes for their patients. Current pressure-measuring methods only provide an occasional snapshot of LAP, and are unable to capture pressure increases in an early stage. The limitations on current LAP measurement methods are a serious impediment to optimal treatment. Current methods need hospitalization, are also inconvenient and uncomfortable, and extremely costly (total cost in average $16,838 per procedure).

Vital Sensors' system will deliver continuous, convenient telemetric measurement of LAP by means of an advanced minimal invasive microelectronic implant, and will give physicians vital but currently unobtainable data that will significantly improve their ability to manage and treat the disease.

Vital Sensors products will represent a breakthrough in treating heart failure patients. By providing LAP measurements on demand or even continuously, conveniently and digitally, Vital Sensors telemetric implants will give clinicians and physicians vastly improved information, and will allow them to detect increase in LAP at a very early stage. Physicians will be able to optimize treatment schedules and to monitor the results of drug therapy with unprecedented precision. Vital Sensors' products will permit the reduction of hospitalization. Medication can be administrated more efficiently, thus decreasing side effects as well as the cost of treatment. Overall reduction of mortality and morbidity of heart failure patients can be achieved.

Vital Sensors' technology has been extensively prototyped for other applications and all elements of the technology have been successfully tested. The Company's product for CHF addresses a market opportunity estimated in excess of EUR 1 billion annually.

Vital Sensors' products use a chip-based pressure sensor and transponder unit that is implanted in the left atrium and provides LAP data via an easy-to-use hand-held reader. The implant is foldable to allow minimal invasive insertion through a catheter. Pressure readings are in digital format and can be downloaded directly to the physician's computer or read out by patients at home.

Medtech Insight, a division of Windhover Information Inc., is the leading provider of business information and market intelligence for the medical technology marketplace. To register for the "In Circulation" conference or for more information on Medtech Insight, please call Scott Pantel at 949-219-0150 or 888-290-2225 toll-free in the U.S., e-mail [e-mail], or visit www.medtechinsight.com.